Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Clues to how alpha-synuclein damages neurons in Parkinson's disease.

Sulzer D.

Mov Disord. 2010;25 Suppl 1:S27-31. doi: 10.1002/mds.22639.

PMID:
20187229
2.

Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.

Sahay S, Ghosh D, Singh PK, Maji SK.

Curr Protein Pept Sci. 2017;18(7):656-676. doi: 10.2174/1389203717666160314151706. Review.

PMID:
26972727
3.

The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.

Benskey MJ, Perez RG, Manfredsson FP.

J Neurochem. 2016 May;137(3):331-59. doi: 10.1111/jnc.13570. Epub 2016 Mar 23. Review.

4.

The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.

Fares MB, Ait-Bouziad N, Dikiy I, Mbefo MK, Jovičić A, Kiely A, Holton JL, Lee SJ, Gitler AD, Eliezer D, Lashuel HA.

Hum Mol Genet. 2014 Sep 1;23(17):4491-509. doi: 10.1093/hmg/ddu165. Epub 2014 Apr 11.

5.

Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis.

Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, Savalle M, Nemani V, Chaudhry FA, Edwards RH, Stefanis L, Sulzer D.

J Neurosci. 2006 Nov 15;26(46):11915-22.

6.

Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?

Kanaan NM, Manfredsson FP.

J Parkinsons Dis. 2012;2(4):249-67. doi: 10.3233/JPD-012138. Review.

7.

Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.

Hansen C, Li JY.

Trends Mol Med. 2012 May;18(5):248-55. doi: 10.1016/j.molmed.2012.03.002. Epub 2012 Apr 13. Review.

PMID:
22503115
8.

Differential regulation of wild-type and mutant alpha-synuclein binding to synaptic membranes by cytosolic factors.

Wislet-Gendebien S, Visanji NP, Whitehead SN, Marsilio D, Hou W, Figeys D, Fraser PE, Bennett SA, Tandon A.

BMC Neurosci. 2008 Sep 22;9:92. doi: 10.1186/1471-2202-9-92.

9.

Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.

Xu S, Chan P.

Biomolecules. 2015 Jun 5;5(2):1122-42. doi: 10.3390/biom5021122. Review.

10.

Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.

Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH.

Neurobiol Dis. 2009 Sep;35(3):385-98. doi: 10.1016/j.nbd.2009.05.023. Epub 2009 Jun 6.

PMID:
19505575
11.

Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.

Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T.

J Neurosci. 2011 Nov 16;31(46):16884-94. doi: 10.1523/JNEUROSCI.3967-11.2011.

12.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095
13.

Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.

Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS.

Environ Health Perspect. 2011 Jun;119(6):807-14. doi: 10.1289/ehp.1003013. Epub 2011 Jan 18.

14.

Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K.

Choong CJ, Say YH.

Neurotoxicology. 2011 Dec;32(6):857-63. doi: 10.1016/j.neuro.2011.05.012. Epub 2011 May 30.

PMID:
21658409
15.

Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.

Perfeito R, Cunha-Oliveira T, Rego AC.

Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3. Review.

PMID:
23743292
16.

Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy.

Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, Hodara R, Fredenburg R, Wu DC, Follenzi A, Dauer W, Przedborski S, Ischiropoulos H, Lansbury PT, Sulzer D, Cuervo AM.

J Clin Invest. 2008 Feb;118(2):777-88. doi: 10.1172/JCI32806.

17.

A calcineurin- and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons.

Luo J, Sun L, Lin X, Liu G, Yu J, Parisiadou L, Xie C, Ding J, Cai H.

Hum Mol Genet. 2014 Dec 15;23(24):6567-74. doi: 10.1093/hmg/ddu377. Epub 2014 Jul 22.

18.

Early Parkinson's disease symptoms in α-synuclein transgenic monkeys.

Niu Y, Guo X, Chen Y, Wang CE, Gao J, Yang W, Kang Y, Si W, Wang H, Yang SH, Li S, Ji W, Li XJ.

Hum Mol Genet. 2015 Apr 15;24(8):2308-17. doi: 10.1093/hmg/ddu748. Epub 2014 Dec 30.

19.

c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease.

Mahul-Mellier AL, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S, Lamontanara AJ, Bisquertt A, Eliezer D, Masliah E, Halliday G, Hantschel O, Lashuel HA.

Hum Mol Genet. 2014 Jun 1;23(11):2858-79. doi: 10.1093/hmg/ddt674. Epub 2014 Jan 9.

20.

Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease.

Roy B, Jackson GR.

Hum Mol Genet. 2014 Jun 1;23(11):3008-23. doi: 10.1093/hmg/ddu011. Epub 2014 Jan 14.

Supplemental Content

Support Center